Bevacizumab, a humanised anti-VEGF monoclonal antibody, has shown a significant response in patients with recurrent ovarian cancer with a significant improvement in progression-free survival, especially in patients with poor prognosis [43]. This evidence concerns the gene VEGFA and ovarian carcinoma.